{"protocolSection": {"identificationModule": {"nctId": "NCT02152371", "orgStudyIdInfo": {"id": "13195"}, "secondaryIdInfos": [{"id": "H9X-MC-GBDI", "type": "OTHER", "domain": "Eli Lilly and Company"}, {"id": "2012-004229-25", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Eli Lilly and Company", "class": "INDUSTRY"}, "briefTitle": "A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes", "officialTitle": "A Randomized, Double-Blind Trial Comparing the Effect of Dulaglutide 1.5 mg With Placebo on Glycemic Control in Patients With Type 2 Diabetes on Basal Insulin Glargine", "acronym": "AWARD-9"}, "statusModule": {"statusVerifiedDate": "2019-09", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2014-05"}, "primaryCompletionDateStruct": {"date": "2015-10", "type": "ACTUAL"}, "completionDateStruct": {"date": "2015-10", "type": "ACTUAL"}, "studyFirstSubmitDate": "2014-05-28", "studyFirstSubmitQcDate": "2014-05-28", "studyFirstPostDateStruct": {"date": "2014-06-02", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2016-10-12", "resultsFirstSubmitQcDate": "2016-10-12", "resultsFirstPostDateStruct": {"date": "2016-12-07", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2019-09-10", "lastUpdatePostDateStruct": {"date": "2019-09-25", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Eli Lilly and Company", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The main purpose of this study is to evaluate the use of the study drug known as dulaglutide in participants with type II diabetes who are taking once-daily insulin glargine. The study will last about 31 weeks for each participant."}, "conditionsModule": {"conditions": ["Diabetes Mellitus, Type 2"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 300, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Dulaglutide + Insulin Glargine", "type": "EXPERIMENTAL", "description": "1.5 milligrams (mg) dulaglutide administered subcutaneously (SQ) once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses.", "interventionNames": ["Drug: Dulaglutide", "Drug: Insulin Glargine", "Drug: Metformin"]}, {"label": "Placebo + Insulin Glargine", "type": "PLACEBO_COMPARATOR", "description": "Placebo administered SQ once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses.", "interventionNames": ["Drug: Placebo", "Drug: Insulin Glargine", "Drug: Metformin"]}], "interventions": [{"type": "DRUG", "name": "Dulaglutide", "description": "Administered SQ", "armGroupLabels": ["Dulaglutide + Insulin Glargine"], "otherNames": ["LY2189265"]}, {"type": "DRUG", "name": "Placebo", "description": "Administered SQ", "armGroupLabels": ["Placebo + Insulin Glargine"]}, {"type": "DRUG", "name": "Insulin Glargine", "description": "Administered SQ", "armGroupLabels": ["Dulaglutide + Insulin Glargine", "Placebo + Insulin Glargine"]}, {"type": "DRUG", "name": "Metformin", "description": "Administered orally", "armGroupLabels": ["Dulaglutide + Insulin Glargine", "Placebo + Insulin Glargine"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline to 28 Weeks in Hemoglobin A1c (HbA1c)", "description": "HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Least-squares (LS) mean and standard error (SE) changes from baseline in HbA1c at 28 weeks were measured using mixed model regression and restricted maximum likelihood (REML) with treatment, pooled country, visit, and treatment-by -visit interaction as fixed effects, baseline as covariate, and participant as a random effect.", "timeFrame": "Baseline, 28 Weeks"}], "secondaryOutcomes": [{"measure": "Change From Baseline to 28 Weeks in Fasting Serum Glucose (FSG)", "description": "FSG is a test to determine glucose levels after an overnight fast. LS means FSG change from baseline to primary endpoint at week 28 was calculated using a mixed effects model for repeated measures (MMRM) analysis adjusted by treatment, country, metformin use, week, treatment-by-week interaction, and baseline FSG as covariate.", "timeFrame": "Baseline, 28 Weeks"}, {"measure": "Change From Baseline to 28 Weeks in 7-Point Self Monitored Plasma Glucose (SMPG)", "description": "The LS means of the 7-point SMPG change from baseline to primary endpoint at week 28 was measured using a MMRM analysis adjusted by treatment, country, metformin use, week, treatment-by-week interaction, and baseline SMPG as covariate.", "timeFrame": "Baseline, 28 Weeks"}, {"measure": "Change From Baseline to 28 Weeks in Body Weight", "description": "LS means of the body weight change from baseline to primary endpoint at week 28 was adjusted by treatment, country, metformin use, week, treatment-by-week interaction, and baseline body weight as covariate, via a MMRM analysis.", "timeFrame": "Baseline, 28 Weeks"}, {"measure": "Change From Baseline to 28 Weeks in Daily Mean Insulin Glargine Dose", "description": "Least Square (LS) Means of the insulin dose change from baseline to primary endpoint at week 28 was adjusted by treatment, country, metformin use, week, treatment-by-week interaction, and baseline insulin dose as covariate, via a MMRM analysis.", "timeFrame": "Baseline, 28 Weeks"}, {"measure": "Number of Participants With Investigator Reported and Adjudicated Cardiovascular Events", "description": "Cardiovascular (CV) adverse events (AEs) were adjudicated by an independent committee of physicians with cardiology expertise external to the sponsor. Deaths occurring during the study treatment period and nonfatal CV AEs were to be adjudicated. Nonfatal CV events that were to be adjudicated were myocardial infarction; hospitalization for unstable angina; hospitalization for heart failure; coronary interventions (such as coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI); and cerebrovascular events, including cerebrovascular accident (CVA/stroke), and transient ischemic attack (TIA).", "timeFrame": "Baseline through 28 Weeks"}, {"measure": "Percentage of Participants With Self-Reported Events of Hypoglycemia", "description": "Hypoglycemic events (HE) were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of =\\<3.9 mmol/L), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of =\\<3.9 mmol/L), nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking), or probable symptomatic (defined as events during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The percentage of participants with self-reported hypoglycemic events is presented.", "timeFrame": "Baseline through 28 Weeks"}, {"measure": "Percentage of Participants Discontinuing the Study Due to Severe, Persistent Hyperglycemia", "timeFrame": "Baseline through 28 Weeks"}, {"measure": "Number of Participants With Adjudicated Acute Pancreatitis Events", "description": "The number of cases of acute pancreatitis confirmed by adjudication. A summary of serious and other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.", "timeFrame": "Baseline through 28 Weeks"}, {"measure": "Number of Participants With Thyroid Tumors/Neoplasms (Including C-Cell Hyperplasia)", "timeFrame": "Baseline through 28 Weeks"}, {"measure": "Number of Participants With Dulaglutide Anti-Drug Antibodies", "description": "Dulaglutide anti-drug antibodies (ADA) were assessed at baseline, Weeks 12 and 28. A participant was considered to have treatment-emergent (TE) dulaglutide ADAs if the participant had at least 1 titer that was TE relative to baseline, defined as a 4-fold or greater increase in titer from baseline measurement.", "timeFrame": "Baseline, Week 12 and Week 28"}, {"measure": "Percentage of Participants Achieving HbA1c Targets of <7.0% or \u22646.5%", "description": "Percentage of participants who achieved HbA1c levels of \\<7% or \u22646.5% were analyzed using a logistic regression model, controlling for treatment, pre-treatment, baseline HbA1c and country.", "timeFrame": "28 Weeks"}, {"measure": "Percentage of Participants Achieving HbA1c Target of <7.0% and Without Weight Gain (<0.1 Kilograms [kg]) at 28 Weeks and Without Documented Symptomatic Hypoglycemia During the Maintenance Period (Weeks 12-28)", "description": "Percentage of participants who achieved a target HbA1c target of \\<7%, without weight gain and without documented symptomatic hypoglycemia at 28 weeks were analyzed using regression model, controlling for treatment, pre-treatment, baseline HbA1c and country.", "timeFrame": "28 Weeks"}, {"measure": "Percentage of Participants Achieving HbA1c Target of <7.0% at 28 Weeks and Without Documented Symptomatic Hypoglycemia During the Maintenance Period (Weeks 12-28)", "description": "Percentage of participants achieving target HbA1c of \\<7.0% at 28 weeks without documented symptomatic hypoglycemia are presented. Documented symptomatic hypoglycemia is defined as any time a participant experienced symptoms and or signs associated with hypoglycemia and had a plasma glucose of \\<=70 mg/dL.", "timeFrame": "28 Weeks"}, {"measure": "Percentage of Participants Achieving HbA1c Target of <7.0% and Without Weight Gain (<0.1 kg)", "timeFrame": "28 Weeks"}, {"measure": "Rate of Hypoglycemic Events up to 28 Weeks", "description": "The rate of total hypoglycemic events any type per 30 days is presented. The hypoglycemia rate per 30 days during defined period is calculated by the number of hypoglycemia events within the period/number of days participant at risk within the period\\*30 days.", "timeFrame": "Baseline through 28 Weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Have type 2 diabetes (based on the World Health Organization's \\[WHO\\] diagnostic criteria)\n* Have been treated with basal insulin glargine once daily with or without metformin for at least 3 months prior to screening\n* Doses of once daily insulin glargine and metformin (if taken) must be stable during the 3-month period prior to screening. Doses of metformin are considered stable if all prescribed doses during this period are in the range between the minimum required dose (\u22651500 mg/day) and the maximum approved dose per the locally-approved label\n* Have an HbA1c value \u22657.0% and \u226410.5% as assessed by the central laboratory at screening\n* Require further insulin glargine dose increase at week 3 per the treat-to-target (TTT) algorithm based on the SMPG data collected during the prior week\n* Have stable weight (\u00b15%) \u22653 months prior to screening\n* Have body mass index (BMI) \u226445 kilograms per square meter (kg/m\\^2) at screening\n* Are able and willing to administer once weekly randomized therapy\n* Are females of childbearing potential who must:\n\n  * Test negative for pregnancy at screening, based on a serum pregnancy test\n  * Agree to use a reliable method of birth control\n  * Not be breastfeeding\n\nExclusion Criteria:\n\n* Have been treated with ANY other antihyperglycemia regimen, other than basal insulin glargine once daily with or without metformin, within the 3 months prior to screening or between screening and week 3\n* Have a history of \u22651 episode of ketoacidosis or hyperosmolar state/coma\n* Have a history of hypoglycemia unawareness within the 6 months prior to screening\n* Have been treated with drugs that promote weight loss within the 3 months prior to screening or between screening and week 3\n* Are receiving chronic (\\>14 days) systemic glucocorticoid therapy or have received such therapy within the 4 weeks prior to screening or between screening and week 3\n* Have had any of the following cardiovascular conditions within the 2 months prior to screening: acute myocardial infarction (MI), New York Heart Association (NYHA) Class III or Class IV heart failure, or cerebrovascular accident (stroke)\n* Have a known clinically significant gastric emptying abnormality or have undergone gastric bypass surgery or restrictive bariatric surgery\n* Have acute or chronic hepatitis, signs and symptoms of any other liver disease, or alanine aminotransferase (ALT) level \\>2.5 times the upper limit of the reference range, as determined by the central laboratory\n* Have a history of chronic pancreatitis or acute idiopathic pancreatitis, or were diagnosed with any type of acute pancreatitis within the 3 months prior to screening\n* Have an estimated glomerular filtration rate (eGFR) \\<30 milliliters/minute/1.73 square meter (mL/min/m\\^2), calculated by the Chronic Kidney Disease-Epidemiology (CKD-EPI) equation, as determined by the central laboratory; for participants on metformin, have renal disease or renal dysfunction (for example, a serum creatinine \u22651.5 mg/deciliter \\[dL\\] \\[male\\] or \u22651.4 mg/dL \\[female\\] or eGFR \\[CKD-EPI\\] \\<60 mL/min/1.73 m\\^2)\n* Have evidence of a significant, uncontrolled endocrine abnormality\n* Have any self or family history of type 2A or type 2B multiple endocrine neoplasia (MEN 2A or 2B) in the absence of known C-cell hyperplasia\n* Have any self or family history of medullary C-cell hyperplasia, focal hyperplasia, or carcinoma (including sporadic, familial, or part of MEN 2A or 2B syndrome)\n* Have serum calcitonin \u226520 picograms/mL, as determined by the central laboratory\n* Have evidence of a significant, active autoimmune abnormality\n* Have any other condition not listed in this section that is a contraindication for use of insulin glargine, or, for participants using metformin, have a condition that is a contraindication for the use of metformin and would require metformin discontinuation per label\n* Have a history of transplanted organ\n* Have a history of active or untreated malignancy, or are in remission from a clinically significant malignancy during the 5 years prior to screening\n* Have a history of any other condition which, in the opinion of the investigator, may preclude the participants from following and completing the protocol\n* Have any hematologic condition that may interfere with HbA1c measurement (eg, hemolytic anemias, sickle-cell disease)", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", "affiliation": "Eli Lilly and Company", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Valley Endocrine, Fresno", "city": "Fresno", "state": "California", "zip": "93720", "country": "United States", "geoPoint": {"lat": 36.74773, "lon": -119.77237}}, {"facility": "Mills-Peninsula Diabetes Research Insitute", "city": "San Mateo", "state": "California", "zip": "94401", "country": "United States", "geoPoint": {"lat": 37.56299, "lon": -122.32553}}, {"facility": "University Clinical Investigators, Inc.", "city": "Tustin", "state": "California", "zip": "92780", "country": "United States", "geoPoint": {"lat": 33.74585, "lon": -117.82617}}, {"facility": "Rocky Mountain Diabetes and Osteoporosis Center", "city": "Idaho Falls", "state": "Idaho", "zip": "83404", "country": "United States", "geoPoint": {"lat": 43.46658, "lon": -112.03414}}, {"facility": "Northwest Endo Diabetes Research, LLC", "city": "Arlington Heights", "state": "Illinois", "zip": "60005", "country": "United States", "geoPoint": {"lat": 42.08836, "lon": -87.98063}}, {"facility": "Cotton O'Neil Clinic", "city": "Topeka", "state": "Kansas", "zip": "66606", "country": "United States", "geoPoint": {"lat": 39.04833, "lon": -95.67804}}, {"facility": "Kentucky Diabetes Endocrinology Center", "city": "Lexington", "state": "Kentucky", "zip": "40503", "country": "United States", "geoPoint": {"lat": 37.98869, "lon": -84.47772}}, {"facility": "AB Clinical Trials", "city": "Las Vegas", "state": "Nevada", "zip": "89119", "country": "United States", "geoPoint": {"lat": 36.17497, "lon": -115.13722}}, {"facility": "SHS Clinical Research Group", "city": "Toms River", "state": "New Jersey", "zip": "08753", "country": "United States", "geoPoint": {"lat": 39.95373, "lon": -74.19792}}, {"facility": "Bland Clinic, PA", "city": "Greensboro", "state": "North Carolina", "zip": "27401", "country": "United States", "geoPoint": {"lat": 36.07264, "lon": -79.79198}}, {"facility": "PMG Research of Knoxville", "city": "Knoxville", "state": "Tennessee", "zip": "37912", "country": "United States", "geoPoint": {"lat": 35.96064, "lon": -83.92074}}, {"facility": "Rainier Clinical Research Center", "city": "Renton", "state": "Washington", "zip": "98057", "country": "United States", "geoPoint": {"lat": 47.48288, "lon": -122.21707}}, {"facility": "Polyclinic", "city": "Seattle", "state": "Washington", "zip": "98104", "country": "United States", "geoPoint": {"lat": 47.60621, "lon": -122.33207}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Beroun", "zip": "26601", "country": "Czechia", "geoPoint": {"lat": 49.96382, "lon": 14.072}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Brandys Nad Labem-Stara Bolesl", "zip": "25001", "country": "Czechia"}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Ceske Budejovice", "zip": "370 01", "country": "Czechia", "geoPoint": {"lat": 48.97447, "lon": 14.47434}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Krnov", "zip": "79401", "country": "Czechia", "geoPoint": {"lat": 50.08967, "lon": 17.70385}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Prague", "zip": "149 00", "country": "Czechia", "geoPoint": {"lat": 50.08804, "lon": 14.42076}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Budapest", "zip": "1139", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Debrecen", "zip": "4043", "country": "Hungary", "geoPoint": {"lat": 47.53333, "lon": 21.63333}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Nagykanizsa", "zip": "8800", "country": "Hungary", "geoPoint": {"lat": 46.45347, "lon": 16.99104}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Monza", "zip": "20900", "country": "Italy", "geoPoint": {"lat": 45.58005, "lon": 9.27246}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Olbia", "zip": "07026", "country": "Italy", "geoPoint": {"lat": 40.92337, "lon": 9.49802}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Pisa", "zip": "56126", "country": "Italy", "geoPoint": {"lat": 43.70853, "lon": 10.4036}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Rome", "zip": "00128", "country": "Italy", "geoPoint": {"lat": 41.89193, "lon": 12.51133}}, {"facility": "Centro de Endocrinologia y Nutricion del Turabo", "city": "Caguas", "zip": "00726", "country": "Puerto Rico", "geoPoint": {"lat": 18.23412, "lon": -66.0485}}, {"facility": "Manati Center for Clinical Research Inc", "city": "Manati", "zip": "00674", "country": "Puerto Rico", "geoPoint": {"lat": 18.42745, "lon": -66.49212}}, {"facility": "Ponce School of Medicine CAIMED Center", "city": "Ponce", "zip": "00716", "country": "Puerto Rico", "geoPoint": {"lat": 18.01108, "lon": -66.61406}}, {"facility": "Endocrine Lipid Diabetes Research Institute", "city": "Ponce", "zip": "00717-2075", "country": "Puerto Rico", "geoPoint": {"lat": 18.01108, "lon": -66.61406}}, {"facility": "GCM Medical Group PSC", "city": "San Juan", "zip": "00909", "country": "Puerto Rico", "geoPoint": {"lat": 18.46633, "lon": -66.10572}}, {"facility": "American Telemedicine Center", "city": "San Juan", "zip": "00917-3104", "country": "Puerto Rico", "geoPoint": {"lat": 18.46633, "lon": -66.10572}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Alzira", "zip": "46600", "country": "Spain", "geoPoint": {"lat": 39.15, "lon": -0.43333}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Cadiz", "zip": "11540", "country": "Spain", "geoPoint": {"lat": 36.52672, "lon": -6.2891}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Madrid", "zip": "28223", "country": "Spain", "geoPoint": {"lat": 40.4165, "lon": -3.70256}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Sevilla", "zip": "41010", "country": "Spain", "geoPoint": {"lat": 37.38283, "lon": -5.97317}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Teruel", "zip": "44002", "country": "Spain", "geoPoint": {"lat": 40.3456, "lon": -1.10646}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Mortimer", "state": "Berks", "zip": "RG7 3SQ", "country": "United Kingdom"}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Leicester", "state": "Leicestershire", "zip": "LE5 4PW", "country": "United Kingdom", "geoPoint": {"lat": 52.6386, "lon": -1.13169}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Guildford", "state": "Surrey", "zip": "GU2 7XX", "country": "United Kingdom", "geoPoint": {"lat": 51.23536, "lon": -0.57427}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Swansea", "state": "Wales", "zip": "SA6 6NL", "country": "United Kingdom", "geoPoint": {"lat": 51.62079, "lon": -3.94323}}]}, "referencesModule": {"references": [{"pmid": "29430801", "type": "DERIVED", "citation": "Pantalone KM, Patel H, Yu M, Fernandez Lando L. Dulaglutide 1.5 mg as an add-on option for patients uncontrolled on insulin: Subgroup analysis by age, duration of diabetes and baseline glycated haemoglobin concentration. Diabetes Obes Metab. 2018 Jun;20(6):1461-1469. doi: 10.1111/dom.13252. Epub 2018 Mar 23."}, {"pmid": "29110972", "type": "DERIVED", "citation": "Yu M, Brunt KV, Milicevic Z, Varnado O, Boye KS. Patient-reported Outcomes in Patients with Type 2 Diabetes Treated with Dulaglutide Added to Titrated Insulin Glargine (AWARD-9). Clin Ther. 2017 Nov;39(11):2284-2295. doi: 10.1016/j.clinthera.2017.10.002. Epub 2017 Oct 27."}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.", "infoTypes": ["STUDY_PROTOCOL", "SAP", "CSR"], "timeFrame": "Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.", "accessCriteria": "A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.", "url": "https://vivli.org/"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "All eligible participants entered a 2-week lead-in period. Only those participants who required further up-titration of the insulin glargine dose per treat-to-target (TTT) algorithm were randomized to one of two treatment groups.", "groups": [{"id": "FG000", "title": "Dulaglutide + Insulin Glargine", "description": "1.5 milligrams (mg) dulaglutide administered subcutaneously (SQ) once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses."}, {"id": "FG001", "title": "Placebo + Insulin Glargine", "description": "Placebo administered SQ once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "150"}, {"groupId": "FG001", "numSubjects": "150"}]}, {"type": "Received at Least 1 Dose of Study Drug.", "achievements": [{"groupId": "FG000", "numSubjects": "150"}, {"groupId": "FG001", "numSubjects": "150"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "138"}, {"groupId": "FG001", "numSubjects": "134"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "12"}, {"groupId": "FG001", "numSubjects": "16"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "7"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Reason Not Given", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "All participants who received at least 1 dose of study drug.", "groups": [{"id": "BG000", "title": "Dulaglutide + Insulin Glargine", "description": "1.5 milligrams (mg) dulaglutide administered subcutaneously (SQ) once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses."}, {"id": "BG001", "title": "Placebo + Insulin Glargine", "description": "Placebo administered SQ once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "150"}, {"groupId": "BG001", "value": "150"}, {"groupId": "BG002", "value": "300"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "60.2", "spread": "9.47"}, {"groupId": "BG001", "value": "60.6", "spread": "10.07"}, {"groupId": "BG002", "value": "60.4", "spread": "9.76"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "65"}, {"groupId": "BG001", "value": "62"}, {"groupId": "BG002", "value": "127"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "85"}, {"groupId": "BG001", "value": "88"}, {"groupId": "BG002", "value": "173"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "26"}, {"groupId": "BG001", "value": "25"}, {"groupId": "BG002", "value": "51"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "104"}, {"groupId": "BG001", "value": "104"}, {"groupId": "BG002", "value": "208"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "20"}, {"groupId": "BG001", "value": "21"}, {"groupId": "BG002", "value": "41"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "3"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "11"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "143"}, {"groupId": "BG001", "value": "138"}, {"groupId": "BG002", "value": "281"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "4"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Czech Republic", "categories": [{"measurements": [{"groupId": "BG000", "value": "25"}, {"groupId": "BG001", "value": "27"}, {"groupId": "BG002", "value": "52"}]}]}, {"title": "Puerto Rico", "categories": [{"measurements": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "28"}]}]}, {"title": "Hungary", "categories": [{"measurements": [{"groupId": "BG000", "value": "37"}, {"groupId": "BG001", "value": "35"}, {"groupId": "BG002", "value": "72"}]}]}, {"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "32"}, {"groupId": "BG001", "value": "29"}, {"groupId": "BG002", "value": "61"}]}]}, {"title": "Italy", "categories": [{"measurements": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "15"}, {"groupId": "BG002", "value": "28"}]}]}, {"title": "United Kingdom", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "4"}]}]}, {"title": "Spain", "categories": [{"measurements": [{"groupId": "BG000", "value": "29"}, {"groupId": "BG001", "value": "26"}, {"groupId": "BG002", "value": "55"}]}]}]}, {"title": "Mean Insulin Glargine Dose", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Units (U)", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "40.71", "spread": "23.12"}, {"groupId": "BG001", "value": "36.59", "spread": "21.46"}, {"groupId": "BG002", "value": "38.65", "spread": "22.37"}]}]}]}, {"title": "Metformin Use at Baseline", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Treated with Metformin", "categories": [{"measurements": [{"groupId": "BG000", "value": "134"}, {"groupId": "BG001", "value": "131"}, {"groupId": "BG002", "value": "265"}]}]}, {"title": "Not Treated with Metformin", "categories": [{"measurements": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "19"}, {"groupId": "BG002", "value": "35"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline to 28 Weeks in Hemoglobin A1c (HbA1c)", "description": "HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Least-squares (LS) mean and standard error (SE) changes from baseline in HbA1c at 28 weeks were measured using mixed model regression and restricted maximum likelihood (REML) with treatment, pooled country, visit, and treatment-by -visit interaction as fixed effects, baseline as covariate, and participant as a random effect.", "populationDescription": "All participants who received at least one dose of study drug and had evaluable baseline and post- baseline HbA1c.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage of change", "timeFrame": "Baseline, 28 Weeks", "groups": [{"id": "OG000", "title": "Dulaglutide + Insulin Glargine", "description": "1.5 milligrams (mg) dulaglutide administered subcutaneously (SQ) once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses.\n\nDulaglutide: Administered SQ\n\nInsulin Glargine: Administered SQ\n\nMetformin: Administered orally"}, {"id": "OG001", "title": "Placebo + Insulin Glargine", "description": "Placebo administered SQ once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses.\n\nPlacebo: Administered SQ\n\nInsulin Glargine: Administered SQ\n\nMetformin: Administered orally"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "150"}, {"groupId": "OG001", "value": "150"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.44", "spread": "0.09"}, {"groupId": "OG001", "value": "-0.67", "spread": "0.09"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<.001", "statisticalMethod": "Mixed Model for Repeated Measures (MMRM)", "paramType": "LS Means Diff", "paramValue": "-0.77", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.97", "ciUpperLimit": "-0.56", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.10"}]}, {"type": "SECONDARY", "title": "Change From Baseline to 28 Weeks in Fasting Serum Glucose (FSG)", "description": "FSG is a test to determine glucose levels after an overnight fast. LS means FSG change from baseline to primary endpoint at week 28 was calculated using a mixed effects model for repeated measures (MMRM) analysis adjusted by treatment, country, metformin use, week, treatment-by-week interaction, and baseline FSG as covariate.", "populationDescription": "All participants who received at least one dose of study drug and had evaluable baseline and post-baseline FSG data.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "milligram per deciliter (mg/dL)", "timeFrame": "Baseline, 28 Weeks", "groups": [{"id": "OG000", "title": "Dulaglutide + Insulin Glargine", "description": "1.5 milligrams (mg) dulaglutide administered subcutaneously (SQ) once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses.\n\nDulaglutide: Administered SQ\n\nInsulin Glargine: Administered SQ\n\nMetformin: Administered orally"}, {"id": "OG001", "title": "Placebo + Insulin Glargine", "description": "Placebo administered SQ once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses.\n\nPlacebo: Administered SQ\n\nInsulin Glargine: Administered SQ\n\nMetformin: Administered orally"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "150"}, {"groupId": "OG001", "value": "150"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-44.63", "spread": "4.16"}, {"groupId": "OG001", "value": "-27.90", "spread": "4.08"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<.001", "statisticalMethod": "Mixed Models Analysis", "paramType": "LS Mean Diff", "paramValue": "-16.73", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-26.02", "ciUpperLimit": "-7.44", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "4.72"}]}, {"type": "SECONDARY", "title": "Change From Baseline to 28 Weeks in 7-Point Self Monitored Plasma Glucose (SMPG)", "description": "The LS means of the 7-point SMPG change from baseline to primary endpoint at week 28 was measured using a MMRM analysis adjusted by treatment, country, metformin use, week, treatment-by-week interaction, and baseline SMPG as covariate.", "populationDescription": "All randomized participants who received at least 1 dose of study drug and had evaluable baseline and post-baseline SMPG data.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline, 28 Weeks", "groups": [{"id": "OG000", "title": "Dulaglutide + Insulin Glargine", "description": "1.5 milligrams (mg) dulaglutide administered subcutaneously (SQ) once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses.\n\nDulaglutide: Administered SQ\n\nInsulin Glargine: Administered SQ\n\nMetformin: Administered orally"}, {"id": "OG001", "title": "Placebo + Insulin Glargine", "description": "Placebo administered SQ once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses.\n\nPlacebo: Administered SQ\n\nInsulin Glargine: Administered SQ\n\nMetformin: Administered orally"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "150"}, {"groupId": "OG001", "value": "150"}]}], "classes": [{"title": "Pre-Morning Meal (n=133,129)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-44.03", "spread": "2.71"}, {"groupId": "OG001", "value": "-35.97", "spread": "2.64"}]}]}, {"title": "Morning Meal 2-Hour Postprandial (n=123,119)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-64.16", "spread": "4.31"}, {"groupId": "OG001", "value": "-46.97", "spread": "4.27"}]}]}, {"title": "Pre-Midday Meal (n=133,127)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-40.89", "spread": "3.72"}, {"groupId": "OG001", "value": "-25.34", "spread": "3.62"}]}]}, {"title": "Midday Meal 2-Hour Post Prandial (n=123,117)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-51.13", "spread": "4.40"}, {"groupId": "OG001", "value": "-32.98", "spread": "4.33"}]}]}, {"title": "Pre-Evening Meal (n=133,129)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-43.68", "spread": "4.21"}, {"groupId": "OG001", "value": "-28.71", "spread": "4.07"}]}]}, {"title": "Evening Meal 2-Hour Postprandial (n=126,122)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-48.63", "spread": "5.22"}, {"groupId": "OG001", "value": "-27.35", "spread": "5.16"}]}]}, {"title": "3:00 AM (Morning) (n=124,117)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-39.77", "spread": "4.27"}, {"groupId": "OG001", "value": "-20.30", "spread": "4.23"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Pre-Morning Meal", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": ".007", "statisticalMethod": "Mixed Models Analysis", "paramType": "LS Mean Diff", "paramValue": "-8.06", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-13.87", "ciUpperLimit": "-2.25", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "2.95"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Morning Meal 2-Hour Postprandial", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<.001", "statisticalMethod": "Mixed Models Analysis", "paramType": "LS Mean Diff", "paramValue": "-17.18", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-25.96", "ciUpperLimit": "-8.40", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "4.45"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Pre-Midday Meal", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<.001", "statisticalMethod": "Mixed Models Analysis", "paramType": "LS Mean Diff", "paramValue": "-15.55", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-23.58", "ciUpperLimit": "-7.52", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "4.08"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Midday Meal 2-Hour Postprandial", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<.001", "statisticalMethod": "Mixed Models Analysis", "paramType": "LS Mean Diff", "paramValue": "-18.15", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-27.18", "ciUpperLimit": "-9.12", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "4.58"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Pre-Evening Meal", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": ".001", "statisticalMethod": "Mixed Models Analysis", "paramType": "LS Mean Diff", "paramValue": "-14.96", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-23.93", "ciUpperLimit": "-5.99", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "4.55"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Evening Meal 2-Hour Postprandial", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<.001", "statisticalMethod": "Mixed Models Analysis", "paramType": "LS Mean Diff", "paramValue": "-21.28", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-32.46", "ciUpperLimit": "-10.10", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "5.68"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "3:00AM (Morning)", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<.001", "statisticalMethod": "Mixed Models Analysis", "paramType": "LS Mean Diff", "paramValue": "-19.48", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-28.77", "ciUpperLimit": "-10.18", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "4.72"}]}, {"type": "SECONDARY", "title": "Change From Baseline to 28 Weeks in Body Weight", "description": "LS means of the body weight change from baseline to primary endpoint at week 28 was adjusted by treatment, country, metformin use, week, treatment-by-week interaction, and baseline body weight as covariate, via a MMRM analysis.", "populationDescription": "All participants who received at least one dose of study drug and had evaluable baseline and post-baseline body weight data.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "kilogram(kg)", "timeFrame": "Baseline, 28 Weeks", "groups": [{"id": "OG000", "title": "Dulaglutide + Insulin Glargine", "description": "1.5 milligrams (mg) dulaglutide administered subcutaneously (SQ) once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses.\n\nDulaglutide: Administered SQ\n\nInsulin Glargine: Administered SQ\n\nMetformin: Administered orally"}, {"id": "OG001", "title": "Placebo + Insulin Glargine", "description": "Placebo administered SQ once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses.\n\nPlacebo: Administered SQ\n\nInsulin Glargine: Administered SQ\n\nMetformin: Administered orally"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "150"}, {"groupId": "OG001", "value": "150"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.91", "spread": "0.30"}, {"groupId": "OG001", "value": "0.50", "spread": "0.30"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<.001", "statisticalMethod": "Mixed Models Analysis", "paramType": "LS Means Difference", "paramValue": "-2.41", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.19", "ciUpperLimit": "-1.64", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.39"}]}, {"type": "SECONDARY", "title": "Change From Baseline to 28 Weeks in Daily Mean Insulin Glargine Dose", "description": "Least Square (LS) Means of the insulin dose change from baseline to primary endpoint at week 28 was adjusted by treatment, country, metformin use, week, treatment-by-week interaction, and baseline insulin dose as covariate, via a MMRM analysis.", "populationDescription": "All participants who one dose of study drug and had evaluable baseline and post-baseline insulin glargine data.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units (u)", "timeFrame": "Baseline, 28 Weeks", "groups": [{"id": "OG000", "title": "Dulaglutide + Insulin Glargine", "description": "1.5 milligrams (mg) dulaglutide administered subcutaneously (SQ) once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses.\n\nDulaglutide: Administered SQ\n\nInsulin Glargine: Administered SQ\n\nMetformin: Administered orally"}, {"id": "OG001", "title": "Placebo + Insulin Glargine", "description": "Placebo administered SQ once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses.\n\nPlacebo: Administered SQ\n\nInsulin Glargine: Administered SQ\n\nMetformin: Administered orally"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "150"}, {"groupId": "OG001", "value": "150"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "12.75", "spread": "2.27"}, {"groupId": "OG001", "value": "25.94", "spread": "2.30"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<.001", "statisticalMethod": "MMRM", "paramType": "LS Means Diff", "paramValue": "-13.19", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-19.55", "ciUpperLimit": "-6.84", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "3.21"}]}, {"type": "SECONDARY", "title": "Number of Participants With Investigator Reported and Adjudicated Cardiovascular Events", "description": "Cardiovascular (CV) adverse events (AEs) were adjudicated by an independent committee of physicians with cardiology expertise external to the sponsor. Deaths occurring during the study treatment period and nonfatal CV AEs were to be adjudicated. Nonfatal CV events that were to be adjudicated were myocardial infarction; hospitalization for unstable angina; hospitalization for heart failure; coronary interventions (such as coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI); and cerebrovascular events, including cerebrovascular accident (CVA/stroke), and transient ischemic attack (TIA).", "populationDescription": "All randomized participants who received at least 1 dose of study.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline through 28 Weeks", "groups": [{"id": "OG000", "title": "Dulaglutide + Insulin Glargine", "description": "1.5 milligrams (mg) dulaglutide administered subcutaneously (SQ) once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses.\n\nDulaglutide: Administered SQ\n\nInsulin Glargine: Administered SQ\n\nMetformin: Administered orally"}, {"id": "OG001", "title": "Placebo + Insulin Glargine", "description": "Placebo administered SQ once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses.\n\nPlacebo: Administered SQ\n\nInsulin Glargine: Administered SQ\n\nMetformin: Administered orally"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "150"}, {"groupId": "OG001", "value": "150"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "1"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With Self-Reported Events of Hypoglycemia", "description": "Hypoglycemic events (HE) were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of =\\<3.9 mmol/L), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of =\\<3.9 mmol/L), nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking), or probable symptomatic (defined as events during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The percentage of participants with self-reported hypoglycemic events is presented.", "populationDescription": "All randomized participants who received at least 1 dose of study drug.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Baseline through 28 Weeks", "groups": [{"id": "OG000", "title": "Dulaglutide + Insulin Glargine", "description": "1.5 milligrams (mg) dulaglutide administered subcutaneously (SQ) once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses.\n\nDulaglutide: Administered SQ\n\nInsulin Glargine: Administered SQ\n\nMetformin: Administered orally"}, {"id": "OG001", "title": "Placebo + Insulin Glargine", "description": "Placebo administered SQ once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses.\n\nPlacebo: Administered SQ\n\nInsulin Glargine: Administered SQ\n\nMetformin: Administered orally"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "150"}, {"groupId": "OG001", "value": "150"}]}], "classes": [{"title": "Symptomatic", "categories": [{"measurements": [{"groupId": "OG000", "value": "35.3"}, {"groupId": "OG001", "value": "30.0"}]}]}, {"title": "Asymptomatic", "categories": [{"measurements": [{"groupId": "OG000", "value": "42.7"}, {"groupId": "OG001", "value": "39.3"}]}]}, {"title": "Severe", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.7"}, {"groupId": "OG001", "value": "0.0"}]}]}, {"title": "Nocturnal", "categories": [{"measurements": [{"groupId": "OG000", "value": "28.0"}, {"groupId": "OG001", "value": "28.7"}]}]}, {"title": "Probable Symptomatic", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.7"}, {"groupId": "OG001", "value": "2.0"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants Discontinuing the Study Due to Severe, Persistent Hyperglycemia", "populationDescription": "All randomized participants who received at least 1 dose of study drug.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Baseline through 28 Weeks", "groups": [{"id": "OG000", "title": "Dulaglutide + Insulin Glargine", "description": "1.5 milligrams (mg) dulaglutide administered subcutaneously (SQ) once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses.\n\nDulaglutide: Administered SQ\n\nInsulin Glargine: Administered SQ\n\nMetformin: Administered orally"}, {"id": "OG001", "title": "Placebo + Insulin Glargine", "description": "Placebo administered SQ once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses.\n\nPlacebo: Administered SQ\n\nInsulin Glargine: Administered SQ\n\nMetformin: Administered orally"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "150"}, {"groupId": "OG001", "value": "150"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Adjudicated Acute Pancreatitis Events", "description": "The number of cases of acute pancreatitis confirmed by adjudication. A summary of serious and other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.", "populationDescription": "All randomized participants who received at least 1 dose of study drug.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline through 28 Weeks", "groups": [{"id": "OG000", "title": "Dulaglutide + Insulin Glargine", "description": "1.5 milligrams (mg) dulaglutide administered subcutaneously (SQ) once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses.\n\nDulaglutide: Administered SQ\n\nInsulin Glargine: Administered SQ\n\nMetformin: Administered orally"}, {"id": "OG001", "title": "Placebo + Insulin Glargine", "description": "Placebo administered SQ once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses.\n\nPlacebo: Administered SQ\n\nInsulin Glargine: Administered SQ\n\nMetformin: Administered orally"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "150"}, {"groupId": "OG001", "value": "150"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Thyroid Tumors/Neoplasms (Including C-Cell Hyperplasia)", "populationDescription": "All randomized participants who received at least 1 dose of study drug.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline through 28 Weeks", "groups": [{"id": "OG000", "title": "Dulaglutide + Insulin Glargine", "description": "1.5 milligrams (mg) dulaglutide administered subcutaneously (SQ) once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses.\n\nDulaglutide: Administered SQ\n\nInsulin Glargine: Administered SQ\n\nMetformin: Administered orally"}, {"id": "OG001", "title": "Placebo + Insulin Glargine", "description": "Placebo administered SQ once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses.\n\nPlacebo: Administered SQ\n\nInsulin Glargine: Administered SQ\n\nMetformin: Administered orally"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "150"}, {"groupId": "OG001", "value": "150"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Dulaglutide Anti-Drug Antibodies", "description": "Dulaglutide anti-drug antibodies (ADA) were assessed at baseline, Weeks 12 and 28. A participant was considered to have treatment-emergent (TE) dulaglutide ADAs if the participant had at least 1 titer that was TE relative to baseline, defined as a 4-fold or greater increase in titer from baseline measurement.", "populationDescription": "All randomized participants who received at least 1 dose of study drug and had at least one post-baseline Dulaglutide ADA test result.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline, Week 12 and Week 28", "groups": [{"id": "OG000", "title": "Dulaglutide + Insulin Glargine", "description": "1.5 milligrams (mg) dulaglutide administered subcutaneously (SQ) once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses.\n\nDulaglutide: Administered SQ\n\nInsulin Glargine: Administered SQ\n\nMetformin: Administered orally"}, {"id": "OG001", "title": "Placebo + Insulin Glargine", "description": "Placebo administered SQ once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses.\n\nPlacebo: Administered SQ\n\nInsulin Glargine: Administered SQ\n\nMetformin: Administered orally"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "149"}, {"groupId": "OG001", "value": "149"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants Achieving HbA1c Targets of <7.0% or \u22646.5%", "description": "Percentage of participants who achieved HbA1c levels of \\<7% or \u22646.5% were analyzed using a logistic regression model, controlling for treatment, pre-treatment, baseline HbA1c and country.", "populationDescription": "All randomized participants who received at least 1 dose of study drug and had a baseline and post-baseline HbA1c data. Last observation carried forward (LOCF) methodology was used to impute missing post-baseline values.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "28 Weeks", "groups": [{"id": "OG000", "title": "Dulaglutide + Insulin Glargine", "description": "1.5 milligrams (mg) dulaglutide administered subcutaneously (SQ) once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses.\n\nDulaglutide: Administered SQ\n\nInsulin Glargine: Administered SQ\n\nMetformin: Administered orally"}, {"id": "OG001", "title": "Placebo + Insulin Glargine", "description": "Placebo administered SQ once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses.\n\nPlacebo: Administered SQ\n\nInsulin Glargine: Administered SQ\n\nMetformin: Administered orally"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "150"}, {"groupId": "OG001", "value": "150"}]}], "classes": [{"title": "HbA1c <= 6.5", "categories": [{"measurements": [{"groupId": "OG000", "value": "50.7"}, {"groupId": "OG001", "value": "16.7"}]}]}, {"title": "HbA1c < 7.0", "categories": [{"measurements": [{"groupId": "OG000", "value": "69.3"}, {"groupId": "OG001", "value": "35.3"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<.001", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio (OR)", "paramValue": "6.66", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "3.70", "ciUpperLimit": "12.00"}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<.001", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio, log", "paramValue": "5.71", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "3.35", "ciUpperLimit": "9.73"}]}, {"type": "SECONDARY", "title": "Percentage of Participants Achieving HbA1c Target of <7.0% and Without Weight Gain (<0.1 Kilograms [kg]) at 28 Weeks and Without Documented Symptomatic Hypoglycemia During the Maintenance Period (Weeks 12-28)", "description": "Percentage of participants who achieved a target HbA1c target of \\<7%, without weight gain and without documented symptomatic hypoglycemia at 28 weeks were analyzed using regression model, controlling for treatment, pre-treatment, baseline HbA1c and country.", "populationDescription": "All randomized participants who received at least 1 dose of study drug and had baseline and post-baseline HbA1c data.Last observation carried forward (LOCF) methodology was used to impute missing post-baseline values.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "28 Weeks", "groups": [{"id": "OG000", "title": "Dulaglutide + Insulin Glargine", "description": "1.5 milligrams (mg) dulaglutide administered subcutaneously (SQ) once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses.\n\nDulaglutide: Administered SQ\n\nInsulin Glargine: Administered SQ\n\nMetformin: Administered orally"}, {"id": "OG001", "title": "Placebo + Insulin Glargine", "description": "Placebo administered SQ once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses.\n\nPlacebo: Administered SQ\n\nInsulin Glargine: Administered SQ\n\nMetformin: Administered orally"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "150"}, {"groupId": "OG001", "value": "150"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "40.7"}, {"groupId": "OG001", "value": "16.7"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<.001", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio (OR)", "paramValue": "4.17", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "2.32", "ciUpperLimit": "7.47"}]}, {"type": "SECONDARY", "title": "Percentage of Participants Achieving HbA1c Target of <7.0% at 28 Weeks and Without Documented Symptomatic Hypoglycemia During the Maintenance Period (Weeks 12-28)", "description": "Percentage of participants achieving target HbA1c of \\<7.0% at 28 weeks without documented symptomatic hypoglycemia are presented. Documented symptomatic hypoglycemia is defined as any time a participant experienced symptoms and or signs associated with hypoglycemia and had a plasma glucose of \\<=70 mg/dL.", "populationDescription": "All randomized participants who received at least 1 dose of study drug and had baseline and post-baseline HbA1c data. Last observation carried forward (LOCF) methodology was used to impute missing post-baseline values", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "28 Weeks", "groups": [{"id": "OG000", "title": "Dulaglutide + Insulin Glargine", "description": "1.5 milligrams (mg) dulaglutide administered subcutaneously (SQ) once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses.\n\nDulaglutide: Administered SQ\n\nInsulin Glargine: Administered SQ\n\nMetformin: Administered orally"}, {"id": "OG001", "title": "Placebo + Insulin Glargine", "description": "Placebo administered SQ once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses.\n\nPlacebo: Administered SQ\n\nInsulin Glargine: Administered SQ\n\nMetformin: Administered orally"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "150"}, {"groupId": "OG001", "value": "150"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "52.0"}, {"groupId": "OG001", "value": "28.0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<.001", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio (OR)", "paramValue": "3.61", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "2.09", "ciUpperLimit": "6.23"}]}, {"type": "SECONDARY", "title": "Percentage of Participants Achieving HbA1c Target of <7.0% and Without Weight Gain (<0.1 kg)", "populationDescription": "All randomized participants who received at least 1 dose of study drug and had baseline and post-baseline HbA1c data. Last observation carried forward (LOCF) methodology was used to impute missing post-baseline values.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "28 Weeks", "groups": [{"id": "OG000", "title": "Dulaglutide + Insulin Glargine", "description": "1.5 milligrams (mg) dulaglutide administered subcutaneously (SQ) once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses.\n\nDulaglutide: Administered SQ\n\nInsulin Glargine: Administered SQ\n\nMetformin: Administered orally"}, {"id": "OG001", "title": "Placebo + Insulin Glargine", "description": "Placebo administered SQ once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses.\n\nPlacebo: Administered SQ\n\nInsulin Glargine: Administered SQ\n\nMetformin: Administered orally"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "150"}, {"groupId": "OG001", "value": "150"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "52.7"}, {"groupId": "OG001", "value": "20.0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<.001", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio (OR)", "paramValue": "5.60", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "3.26", "ciUpperLimit": "9.62"}]}, {"type": "SECONDARY", "title": "Rate of Hypoglycemic Events up to 28 Weeks", "description": "The rate of total hypoglycemic events any type per 30 days is presented. The hypoglycemia rate per 30 days during defined period is calculated by the number of hypoglycemia events within the period/number of days participant at risk within the period\\*30 days.", "populationDescription": "All randomized participants who received at least 1 dose of study drug.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "rate of hypoglycemic events per 30 days", "timeFrame": "Baseline through 28 Weeks", "groups": [{"id": "OG000", "title": "Dulaglutide + Insulin Glargine", "description": "1.5 milligrams (mg) dulaglutide administered subcutaneously (SQ) once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses.\n\nDulaglutide: Administered SQ\n\nInsulin Glargine: Administered SQ\n\nMetformin: Administered orally"}, {"id": "OG001", "title": "Placebo + Insulin Glargine", "description": "Placebo administered SQ once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses.\n\nPlacebo: Administered SQ\n\nInsulin Glargine: Administered SQ\n\nMetformin: Administered orally"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "150"}, {"groupId": "OG001", "value": "150"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.63", "spread": "1.24"}, {"groupId": "OG001", "value": "0.70", "spread": "1.32"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Dulaglutide + Insulin Glargine", "description": "1.5 milligrams (mg) dulaglutide administered subcutaneously (SQ) once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses.\n\nDulaglutide: Administered SQ\n\nInsulin Glargine: Administered SQ\n\nMetformin: Administered orally", "seriousNumAffected": 9, "seriousNumAtRisk": 150, "otherNumAffected": 51, "otherNumAtRisk": 150}, {"id": "EG001", "title": "Placebo + Insulin Glargine", "description": "Placebo administered SQ once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses.\n\nPlacebo: Administered SQ\n\nInsulin Glargine: Administered SQ\n\nMetformin: Administered orally", "seriousNumAffected": 7, "seriousNumAtRisk": 150, "otherNumAffected": 29, "otherNumAtRisk": 150}], "seriousEvents": [{"term": "Angina unstable", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 150}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}]}, {"term": "Bradycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 150}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}]}, {"term": "Coronary artery disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}]}, {"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}]}, {"term": "Non-cardiac chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 150}]}, {"term": "Granulomatous liver disease", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}]}, {"term": "Viral infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 150}]}, {"term": "Lower limb fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}]}, {"term": "Intervertebral disc protrusion", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 150}]}, {"term": "Osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 150}]}, {"term": "Hepatic cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 150}]}, {"term": "Carotid artery stenosis", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}]}, {"term": "Cerebral infarction", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}]}, {"term": "Transient ischaemic attack", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 150}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}]}, {"term": "Skin ulcer", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 150}]}], "otherEvents": [{"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 19, "numAffected": 17, "numAtRisk": 150}, {"groupId": "EG001", "numEvents": 6, "numAffected": 6, "numAtRisk": 150}]}, {"term": "Dyspepsia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 9, "numAffected": 9, "numAtRisk": 150}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 23, "numAffected": 18, "numAtRisk": 150}, {"groupId": "EG001", "numEvents": 3, "numAffected": 2, "numAtRisk": 150}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 11, "numAffected": 9, "numAtRisk": 150}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 6, "numAtRisk": 150}, {"groupId": "EG001", "numEvents": 19, "numAffected": 14, "numAtRisk": 150}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 18, "numAffected": 11, "numAtRisk": 150}, {"groupId": "EG001", "numEvents": 10, "numAffected": 10, "numAtRisk": 150}]}, {"term": "Decreased appetite", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 11, "numAffected": 10, "numAtRisk": 150}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "GT60", "restrictiveAgreement": true}, "pointOfContact": {"title": "Chief Medical Officer", "organization": "Eli Lilly and Company", "phone": "1-800-545-5979"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Czech Republic"]}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Diabetes Mellitus, Type 2", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000069036", "term": "Insulin Glargine"}, {"id": "C000555680", "term": "Dulaglutide"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000097789", "term": "Glucagon-Like Peptide-1 Receptor Agonists"}], "browseLeaves": [{"id": "M10365", "name": "Insulin", "relevance": "LOW"}, {"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M173166", "name": "Insulin, Globin Zinc", "relevance": "LOW"}, {"id": "M347", "name": "Insulin Glargine", "asFound": "Interaction", "relevance": "HIGH"}, {"id": "M258626", "name": "Dulaglutide", "asFound": "Clostridium", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M3401", "name": "Glucagon-Like Peptide-1 Receptor Agonists", "relevance": "LOW"}, {"id": "M9043", "name": "Glucagon", "relevance": "LOW"}, {"id": "M26997", "name": "Glucagon-Like Peptide 1", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Gast", "name": "Gastrointestinal Agents"}]}}, "hasResults": true}